Company Profile
Celldex Therapeutics Stock Price, News & Analysis
- Ticker:
- CLDX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
35.65 USD (+1.05%)
Close
Last updated: July 27, 2026
2.27B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, CLDX closed up 1.05% at $35.65. No new same-company headline was identified in the current news window.
Company overview
Business overview
Celldex Therapeutics is an immunology company focused on mast-cell and inflammatory disease biology. Its pipeline is concentrated in high-unmet-need immune disorders.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Celldex sits in specialty biotechnology.
Business Model Characteristics
The company is driven by clinical proof-of-concept, dose selection, and the possibility of building a differentiated immunology franchise.
Position Within the Biotechnology Landscape
Celldex is a catalyst-heavy immunology name whose stock reacts quickly to data quality and clinical differentiation.
Future catalysts
Celldex's catalysts are barzolvolimab in chronic spontaneous urticaria and the rest of its mast-cell platform. The next readout matters because the story is still highly data-dependent.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
- 02
- 03
- 04
- 05
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
AVTX · Source: Avalo Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Celldex Therapeutics (CLDX)?
Celldex Therapeutics (CLDX) most recently closed at 35.65 USD, a +1.05% move versus the previous session.
What is the market cap of Celldex Therapeutics (CLDX)?
Celldex Therapeutics currently has a market capitalization of 2.27B USD on BioPharmSignal.
What does Celldex Therapeutics do?
Celldex Therapeutics is an immunology company focused on mast-cell and inflammatory disease biology. Its pipeline is concentrated in high-unmet-need immune disorders.
On which exchange is CLDX stock listed?
Celldex Therapeutics (CLDX) is associated with NASDAQ, United States, Biopharma.
What is barzolvolimab?
Celldex's catalysts are barzolvolimab in chronic spontaneous urticaria and the rest of its mast-cell platform.
Which conditions is Celldex Therapeutics targeting with barzolvolimab?
Celldex Therapeutics is associated with immunology based on its company overview and current catalyst commentary.
How does Celldex Therapeutics describe recent progress with barzolvolimab?
Celldex's catalysts are barzolvolimab in chronic spontaneous urticaria and the rest of its mast-cell platform.
What is Celldex?
Celldex Therapeutics is an immunology company focused on mast-cell and inflammatory disease biology.